Introduction to Cleo Diagnostics and the published study

Cleo Diagnostics Limited (ASX: $COV) has announced the publication of a milestone article in the scientific journal 'Cancers', demonstrating the superior performance of its ovarian cancer blood test compared to current clinical workflows. The study confirmed that CLEO's test significantly outperforms the use of CA125 and ultrasound in predicting malignancy, correctly detecting 90% of early-stage cancers compared to only 50% using standard workflows, and can be easily adopted for use into clinical practice.

Executive commentary on the study's significance

Our peer-reviewed publication strategy is delivering gold-standard clinical evidence which is vitally important as we begin to engage with potential early adopters of our technology. Having demonstrated now that the CLEO ovarian cancer blood test is far superior to CA125 and ultrasound in our initial pre-surgical triage market, we open up new dialogue with physicians to consider the potential material benefits that CLEO brings for their patients. More broadly, these encouraging results on early-stage cancer detection provide impetus for us to progress the development of CLEO's screening test for ovarian cancer.

Summary of the study and outlook

The publication of the benchmarking study in the scientific journal 'Cancers' marks a significant milestone for Cleo Diagnostics (ASX: $COV), showcasing the superior performance of its ovarian cancer blood test. The study's findings provide strong evidence supporting the commercial pathway for CLEO's tests, with a focus on delivering appropriate routes to adoption following regulatory approval and market launch. The company's ambition to progress the development of a screening test for ovarian cancer is underpinned by the test's ability to outperform current standard clinical workflows, offering potential material benefits for patients and addressing the urgent unmet worldwide need for accurate and early detection of ovarian cancer.